Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Salmon

Showing results (51-60 of 226) with videos related to

Pageof 23
Sort By:
HIV Clinical Trials|April 30, 2016
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort studyPaola Nasta, Dominique Salmon, Antonella d'Arminio Monforte, et al.
AIDS Patient Care and Stds|January 26, 2010
Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIVChristine Burty, Thierry Prazuck, Francois Truchetet, et al.
The Journal of Antimicrobial Chemotherapy|October 26, 2023
What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics studyLéo Mimram, Sophie Magréault, Younes Kerroumi, et al.
European Journal of Clinical Pharmacology|May 15, 2009
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTJulie Bertrand, Jean-Marc Treluyer, Xavière Panhard, et al.
Scandinavian Journal of Infectious Diseases|August 11, 2005
Opportunistic infections as causes of death in HIV-infected patients in the HAART era in FranceFabrice Bonnet, Charlotte Lewden, Thierry May, et al.
International Journal of Epidemiology|November 25, 2004
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSCharlotte Lewden, Dominique Salmon, Philippe Morlat, et al.
AIDS (London, England)|July 27, 2006
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapyMurielle Mary-Krause, Eric Billaud, Isabelle Poizot-Martin, et al.
Therapeutic Drug Monitoring|April 10, 2007
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adultsFidéline Collin, Geneviève Chêne, Sylvie Retout, et al.
Cancer|July 9, 2004
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapyFabrice Bonnet, Charlotte Lewden, Thierry May, et al.
AIDS (London, England)|April 11, 2006
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adultsChristine Durier, Odile Launay, Vincent Meiffrédy, et al.
Pageof 23

Showing results (51-60 of 226) with videos related to

Sort By:
Pageof 23
HIV Clinical Trials|April 30, 2016
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort studyPaola Nasta, Dominique Salmon, Antonella d'Arminio Monforte, et al.
AIDS Patient Care and Stds|January 26, 2010
Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIVChristine Burty, Thierry Prazuck, Francois Truchetet, et al.
The Journal of Antimicrobial Chemotherapy|October 26, 2023
What clindamycin dose should be administered by continuous infusion during combination therapy with rifampicin? A prospective population pharmacokinetics studyLéo Mimram, Sophie Magréault, Younes Kerroumi, et al.
European Journal of Clinical Pharmacology|May 15, 2009
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTJulie Bertrand, Jean-Marc Treluyer, Xavière Panhard, et al.
Scandinavian Journal of Infectious Diseases|August 11, 2005
Opportunistic infections as causes of death in HIV-infected patients in the HAART era in FranceFabrice Bonnet, Charlotte Lewden, Thierry May, et al.
International Journal of Epidemiology|November 25, 2004
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSCharlotte Lewden, Dominique Salmon, Philippe Morlat, et al.
AIDS (London, England)|July 27, 2006
Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapyMurielle Mary-Krause, Eric Billaud, Isabelle Poizot-Martin, et al.
Therapeutic Drug Monitoring|April 10, 2007
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adultsFidéline Collin, Geneviève Chêne, Sylvie Retout, et al.
Cancer|July 9, 2004
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapyFabrice Bonnet, Charlotte Lewden, Thierry May, et al.
AIDS (London, England)|April 11, 2006
Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adultsChristine Durier, Odile Launay, Vincent Meiffrédy, et al.
Pageof 23